NASDAQ: WBAWalgreens Boots Alliance Inc Stock
$11.74+0.12 (+1.03%)
Updated Jan 23, 2025
WBA Price
$11.74
Fair Value Price
N/A
Market Cap
$10.15B
52 Week Low
$8.08
52 Week High
$23.77
P/E
-1.15x
P/B
1.02x
P/S
0.05x
PEG
N/A
Dividend Yield
8.52%
Revenue
$150.41B
Earnings
-$8.83B
Gross Margin
17.6%
Operating Margin
-4.62%
Profit Margin
-5.9%
Debt to Equity
6.77
Operating Cash Flow
$1B
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
WBA Overview
Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WBA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
D
Momentum
B
Sentiment
B
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
WBA
Ranked#2 of 5
Ranked#2 of 5
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.87 | B | |
| $4.97 | C | |
| $1.68 | D |
Be the first to know about important WBA news, forecast changes, insider trades & much more!
WBA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WBA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WBA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WBA is good value based on its book value relative to its share price (1.02x), compared to the US Pharmaceutical Retailers industry average (1.03x)
P/B vs Industry Valuation
WBA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more WBA due diligence checks available for Premium users.
Valuation
WBA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.15x
Industry
-2.06x
Market
30.03x
WBA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.02x
Industry
1.03x
WBA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WBA's financial health
Profit margin
Revenue
$39.5B
Net Income
-$265.0M
Profit Margin
-0.7%
WBA's Earnings (EBIT) of -$6.94B... subscribe to Premium to read more.
Interest Coverage Financials
WBA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$78.5B
Liabilities
$67.3B
Debt to equity
6.77
WBA's short-term liabilities ($27.45B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WBA's long-term liabilities ($39.81B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WBA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
WBA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$140.0M
Investing
-$76.0M
Financing
-$1.7B
WBA's operating cash flow ($1.16B)... subscribe to Premium to read more.
Debt Coverage Financials
WBA vs Pharmaceutical Retailer Stocks
Walgreens Boots Alliance Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.